Table 1.
Baseline characteristics of participants.
| UX (n = 214) | IFN (n = 28) | GA (n = 15) | DMF (n = 27) | TFN (n = 21) | FNG (n = 22) | aCD20 (n = 29) | P | |
|---|---|---|---|---|---|---|---|---|
| Mean age (SD) [years] | 41.71 (17.41) | 45.00 (11.23) | 37.6 (8.03) | 34.93 (10.91) | 45.29 (9.73) | 35.18 (7.66) | 42.72 (10.17) | 0.044 |
| Sex (female:male) | 67:147 | 24:4 | 13:2 | 22:5 | 17:4 | 16:6 | 21:8 | <0.001 |
| Median MS duration (Range) [years] | NA | 14.5 (26) | 4 (13) | 5 (15) | 7 (24) | 10 (20) | 13 (23) | <0.001 |
| MS type (R:P) | NA | 26:2 | 15:0 | 25:2 | 18:3 | 18:4 | 19:10 | 0.014 |
| Median EDSS (IQR) | NA | 1 (0.5) | 1 (0.5) | 1 (0.5) | 1.5 (1) | 1.5 (1.5) | 2.5 (1.25) | <0.001 |
| Mean duration from second dose to phlebotomy*(SD) [days] | NA | 56.20 (27.76) | 79.15 (39.31) | 58.52 (31.42) | 52.26 (29.29) | 57.28 (33.22) | 61.67 (27.35) | 0.306 |
⁎
number of missing values with respect to DMT: IFN, 13; GA, 2; DMF, 6; TFN, 7; FNG, 4; aCD20, 11.
Abbreviations: UX, unexposed; IFN, interferons; GA, glatiramer acetate; DMF, dimethyl fumarate; TFN, teriflunomide; FNG, fingolimod; aCD20, anti-CD20 therapies; SD, standard deviation; MS, multiple sclerosis; NA, not applicable; R, relapsing; P, progressive; EDSS, expanded disability status scale; IQR, interquartile range;.